KUBOTA PHARMACEUTICAL HOLDINGS CO., LTD.

Kubota Pharmaceutical Holdings Co., Ltd.

4596

JP3266500002

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-01 am EDT			5-day change	1st Jan Change
70 ^JPY	0.00%		0.00%	-12.50%

Mar. 22	Kubota Pharmaceutical Adjusts 2023 Financial Results Following Reevaluation	MT
Mar. 21	Kubota Pharmaceutical Holdings Co., Ltd. Restates Consolidated and Non-Consolidated Financial Results for the Fiscal Year Ended December 31, 2023	CI

Kubota Pharmaceutical Holdings Co., Ltd. Provides Consolidated Financial Guidance for the Year Ending December 31, 2021

November 12, 2021 at 01:00 am EST

Kubota Pharmaceutical Holdings Co., Ltd. provided consolidated financial guidance for the year ending December 31, 2021. For the year, the company expects revenue to be JPY 10 million. Operating loss to be ?2,900 million. Net loss of ?2,800 million or ?62.84 per basic diluted share.

Latest news about Kubota Pharmaceutical Holdings Co., Ltd.

Kubota Pharmaceutical Adjusts 2023 Financial Results Following Reevaluation	Mar. 21	MT
Kubota Pharmaceutical Holdings Co., Ltd. Restates Consolidated and Non-Consolidated Financial Results for the Fiscal Year Ended December 31, 2023	Mar. 21	CI
Kubota Pharmaceutical Holdings Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 14	CI
Kubota Pharmaceutical Holdings Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	Nov. 14	CI
Kubota Pharmaceutical Holdings Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-10	CI
Kubota Pharmaceutical Holdings Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Kubota Pharmaceutical Holdings Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-14	CI
Kubota Pharmaceutical Holdings Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-11-11	CI
Kubota Pharmaceutical Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2022	22-11-11	CI
Kubota Pharmaceutical Holdings Co., Ltd. announced that it expects to receive ¥3.1 million in funding from Barclays Bank PLC, Investment Arm	22-08-14	CI
Kubota Pharmaceutical Holdings Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-12	CI
Kubota Pharmaceutical Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2022	22-08-12	CI
Kubota Pharmaceutical Holdings Co., Ltd. Announces Database Lock for Phase 3 Clinical Trial of Emixustat in Patients with Stargardt Disease and Expected Release of Top-Line Results in August 2022	22-07-27	CI
Kubota Pharmaceutical Holdings Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-13	CI
Kubota Pharmaceutical Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2022	22-05-13	CI
Kubota Pharmaceutical Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2022	22-02-14	CI
Kubota Pharmaceutical Holdings Co., Ltd. Provides Consolidated Financial Guidance for the Year Ending December 31, 2021	21-11-12	CI
Kubota Pharmaceutical Holdings Co., Ltd. Reports Consolidated Financial Results for the Six Months Ended June 30, 2021	21-08-12	CI
Kubota Pharmaceutical Holdings Co., Ltd. Provides Consolidated Financial Guidance for the Year Ending Dec. 31, 2021	21-08-12	CI
Kubota Pharmaceutical Holdings Co., Ltd. Announces Consolidated Earnings Results for the First Quarter Ended March 31, 2021	21-05-13	CI
Kubota Pharmaceutical Holdings Co., Ltd. Provides Earnings Guidance for the Full Year Ending December 31, 2021	21-05-13	CI
Kubota Pharmaceutical Holdings Co., Ltd. Announces Consolidated and Non-Consolidated Earnings Results for the Year Ended December 31, 2020	21-02-12	CI
Kubota Pharmaceutical Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2021	21-02-12	CI
Kubota Pharmaceutical Holdings Co., Ltd. announced that it has received ¥4.59 million in funding from Barclays Bank PLC, Investment Arm	20-07-12	CI
Kubota Pharmaceutical Holdings Co., Ltd. announced that it expects to receive ¥4.59 million in funding from Barclays Bank PLC, Investment Arm	20-06-25	CI

Chart Kubota Pharmaceutical Holdings Co., Ltd.

Duration

Period

Chart Kubota Pharmaceutical Holdings Co., Ltd.

More charts

Company Profile

Kubota Pharmaceutical Holdings Co., Ltd. is a Japan-based company mainly engaged in the operation and management of subsidiaries. Its subsidiaries are mainly engaged in discovering and developing drug candidates to treat and slow the progression of sight-threatening ophthalmic diseases. The Company operates pharmaceutical development segment. It focuses on the development of oral formulation for age-related macular degeneration (AMD), glaucoma and dry eye syndrome.

Sector

Pharmaceuticals

Calendar

2024-05-13 - Q1 2024 Earnings Release

More about the company

	1st Jan change	Capi.
KUBOTA PHARMACEUTICAL HOLDINGS CO., LTD.	-12.50%	25.03M
ELI LILLY AND COMPANY	+33.23%	704B
NOVO NORDISK A/S	+28.59%	577B
JOHNSON & JOHNSON	-3.87%	348B
MERCK & CO., INC.	+18.30%	327B
ABBVIE INC.	+5.45%	288B
ASTRAZENECA PLC	+14.81%	234B
NOVARTIS AG	+4.93%	198B
ROCHE HOLDING AG	-9.78%	194B
AMGEN INC.	-3.87%	147B

Other Pharmaceuticals